Novartis Seeks Eye Care Leadership With Full, $50 Billion Alcon Takeover

Novartis pays $28.1 billion for a further 52 percent stake in Alcon, seeking full control with a further offer to buy out minority shareholders.

More from Archive

More from Pink Sheet